Fairfield, Bush & Co. Oncolytics Biotech Inc Transaction History
Fairfield, Bush & Co.
- $195 Billion
- Q3 2025
Shares
1 transactions
Others Institutions Holding ONCY
# of Institutions
58Shares Held
2.82MCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY383KShares$402,5130.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il382KShares$401,1530.0% of portfolio
-
Marshall Wace, LLP London, X0324KShares$340,1810.0% of portfolio
-
Seeds Investor LLC New York, NY258KShares$271,2210.08% of portfolio
-
Goldman Sachs Group Inc New York, NY209KShares$219,1320.0% of portfolio
About ONCOLYTICS BIOTECH INC
- Ticker ONCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 57,867,400
- Market Cap $60.8M
- Description
- Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...